MAPK8 and neoplasm: Similarly, PD-L1_1 mAb affected intracellular pathways downstream PD-L1 in tumor cells by inhibiting the phosphorylation of Erk, JNK, and P38 in a different fashion with respect to atezolizumab which did not affect the level of p-JNK, and showed only a slight effect on p-P38 [14].